General Information:

Id: 1,976
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Mus musculus
male
leptin receptor-deficient db/db mouse and control (db/m) mouse infected with an adenovirus expressing human ACE2 (Ad-hACE2-eGFP) or the control virus (Ad-eGFP) via injection into the pancreas
article
Reference: Bindom SM et al.(2010) Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59: 2540-2548 [PMID: 20660625]

Interaction Information:

Comment Ad-eGFP treatment had no effect on db/db or db/m fasting blood glucose levels or glucose tolerance at 4, 8, or 16 weeks. On the other hand, ACE2 overexpression significantly decreased fasting blood glucose in diabetic mice at both 8 and 16 weeks of age.
Formal Description
Interaction-ID: 15479

gene/protein

ACE2

decreases_quantity of

drug/chemical compound

Glucose

in blood; after fasting
Drugbank entries Show/Hide entries for ACE2
Comment In 8-week-old db/db mice, Ad-hACE2-eGFP significantly enhanced intraperitoneal glucose tolerance, increased islet insulin content and beta-cell proliferation, and reduced beta-cell apoptosis compared with Ad-eGFP.
Formal Description
Interaction-ID: 15480

gene/protein

ACE2

increases_activity of

intraperitoneal
Drugbank entries Show/Hide entries for ACE2
Comment In 8-week-old db/db mice, Ad-hACE2-eGFP significantly enhanced intraperitoneal glucose tolerance, increased islet insulin content and beta-cell proliferation, and reduced beta-cell apoptosis compared with Ad-eGFP.
Formal Description
Interaction-ID: 15481

gene/protein

ACE2

increases_quantity of

complex/PPI

Insulin

in pancreas, in pancreatic islets
Drugbank entries Show/Hide entries for ACE2
Comment In 8-week-old db/db mice, Ad-hACE2-eGFP significantly enhanced intraperitoneal glucose tolerance, increased islet insulin content and beta-cell proliferation, and reduced beta-cell apoptosis compared with Ad-eGFP.
Formal Description
Interaction-ID: 15482

gene/protein

ACE2

affects_activity of

in pancreas, in pancreatic islets
Drugbank entries Show/Hide entries for ACE2
Comment In 8-week-old db/db mice, Ad-hACE2-eGFP significantly enhanced intraperitoneal glucose tolerance, increased islet insulin content and beta-cell proliferation, and reduced beta-cell apoptosis compared with Ad-eGFP.
Formal Description
Interaction-ID: 15483

gene/protein

ACE2

affects_activity of

in pancreas, in pancreatic islets
Drugbank entries Show/Hide entries for ACE2
Comment ACE2 overexpression had no effect on insulin sensitivity in comparison with Ad-eGFP treatment in diabetic mice.
Formal Description
Interaction-ID: 15484

gene/protein

ACE2

NOT affects_activity of

Drugbank entries Show/Hide entries for ACE2
Comment Angiotensin-(1-7) receptor blockade by D-Ala(7)-Ang-(1-7) prevented the ACE2-mediated improvements in intraperitoneal glucose tolerance, glycemia, and islet function and also impaired insulin sensitivity in both Ad-hACE2-eGFP- and Ad-eGFP-treated db/db mice. D-Ala(7)-Ang-(1-7) had no effect on db/m mice.
Formal Description
Interaction-ID: 15485

gene/protein

MAS1

affects_activity of

gene/protein

ACE2

Drugbank entries Show/Hide entries for ACE2
Comment ACE2 is a target for the prevention of beta-cell dysfunction and apoptosis occurring in type 2 diabetes.
Formal Description
Interaction-ID: 15486

gene/protein

ACE2

affects_activity of

Drugbank entries Show/Hide entries for ACE2